Abstract
From the initial discovery of short-interfering RNA (siRNA) and antisense oligonucleotides for specific gene knockdown at the posttranscriptional level to the current CRISPR-Cas9 system offering gene editing at the genomic level, oligonucleotides, in addition to their biological functions in storing and conveying genetic information, provide the most prominent solutions to targeted gene therapies. Nonetheless, looking into the future of curing cancer and acute diseases, researchers are only cautiously optimistic as the cellular delivery of these polyanionic biomacromolecules is still the biggest hurdle for their therapeutic realization. To overcome the delivery obstacle, oligonucleotides have been encapsulated within or conjugated with delivery vehicles for enhanced membrane penetration, improved payload, and tissue-specific delivery. Such delivery systems include but not limited to virus-based vehicles, gold-nanoparticle vehicles, formulated liposomes, and synthetic polymers. In this chapter, delivery challenges imposed by biological barriers are briefly discussed; followed by recent advances in tissue-specific oligonucleotide delivery utilizing both viral and nonviral delivery vectors, discussing their advantages, and how judicious design and formulation could improve and expand their potential as delivery vehicles.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Montecalvo A, Larregina AT, Shufesky WJ et al (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766
Furusawa M, Nishimura T, Yamaizumi M et al (1974) Injection of foreign substances into single cells by cell fusion. Nature 249:449–450
McNamara JO, Andrechek ER, Wang Y et al (2006) Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005–1015
Dassie JP, Liu X-Y, Thomas GS et al (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849
Rice RR, Muirhead AN, Harrison BT et al (2005) Simple, robust strategies for generating DNA-directed RNA interference constructs, RNA interference. Elsevier, Amsterdam, pp 405–419
Jiang H-L, Choi Y-J, Cho M-H et al (2010) Chitosan and chitosan derivatives as DNA and siRNA carriers, Chitin, chitosan, oligosaccharides and their derivatives. CRC Press, London, pp 377–390
Aied A, Greiser U, Pandit A et al (2013) Polymer gene delivery: overcoming the obstacles. Drug Discov Today 18:1090–1098
Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13:655–672
Naldini L (2015) Gene therapy returns to centre stage. Nature 526:351–360
Naldini L (2011) Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12:301–315
Wittrup A, Lieberman J (2015) Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:543–552
Stewart MP, Sharei A, Ding X et al (2016) In vitro and ex vivo strategies for intracellular delivery. Nature 538:183–192
Yin H, Kanasty RL, Eltoukhy AA et al (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15:541–555
Larocca D, Burg MA, Jensen-Pergakes K et al (2002) Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol 3:45–57
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317
Poul MA, Marks JD (1999) Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 288:203–211
Davidson BL, Harper SQ (2005) Viral delivery of recombinant short hairpin RNAs. Methods Enzymol 392:145–173
Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33–40
Di Giusto DL, Krishnan A, Li L, et al (2010) RNA-based gene therapy for HIV with lentiviral vector modified CD34 cells in patients undergoing transplantation for AIDS-related lymphoma. Issues Sci Transl Med 2(36): 36ra43
Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346–358
Gao G-P, Alvira MR, Wang L et al (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99:11854–11859
Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583–593
Pack DW, Hoffman AS, Pun S et al (2005) Design and development of polymers for gene delivery. Nat Rev Drug Discov 4:581–593
Mintzer MA, Simanek EE (2009) Nonviral vectors for gene delivery. Chem Rev 109:259–302
Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62–68
June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7:280ps7
Seow Y, Wood MJ (2009) Biological gene delivery vehicles: beyond viral vectors. Mol Ther 17:767–777
Li S-D, Huang L (2006) Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13:1313–1319
Zimmermann TS, Lee ACH, Akinc A et al (2006) RNAi-mediated gene silencing in non-human primates. Nature 441:111–114
Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457–1465
Gonzalez H, Hwang SJ, Davis ME (1999) New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 10:1068–1074
Liu Y, Wenning L, Lynch M (2004) New poly (D-glucaramidoamine) s induce DNA nanoparticle formation and efficient gene delivery into mammalian cells. J Am Chem Soc 126(24):7422–7423
Park JS, Yi SW, Kim HJ et al (2016) Receptor-mediated gene delivery into human mesenchymal stem cells using hyaluronic acid-shielded polyethylenimine/pDNA nanogels. Carbohydr Polym 136:791–802
Akinc A, Lynn DM, Anderson DG et al (2003) Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery. J Am Chem Soc 125:5316–5323
Green JJ, Langer R, Anderson DG (2008) A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res 41:749–759
Putnam D, Gentry CA, Pack DW et al (2001) Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A 98:1200–1205
Oberli MA, Reichmuth AM, Dorkin JR et al (2017) Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett 17:1326–1335
Yu AC, Chen H, Chan D et al (2016) Scalable manufacturing of biomimetic moldable hydrogels for industrial applications. Proc Natl Acad Sci U S A 113:14255–14260
Dahlman JE, Kauffman KJ, Xing Y et al (2017) Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc Natl Acad Sci U S A 114:2060–2065
Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129–138
Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286:950–952
Zamore PD, Tuschl T, Sharp PA et al (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25–33
Han M-H, Goud S, Song L et al (2004) The Arabidopsis double-stranded RNA-binding protein HYL1 plays a role in microRNA-mediated gene regulation. Proc Natl Acad Sci U S A 101:1093–1098
Iorio MV, Ferracin M, Liu C-G et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070
Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12:847–865
Roberts TC, Wood MJA (2013) Therapeutic targeting of non-coding RNAs. Essays Biochem 54:127–145
Hobert O (2008) Gene regulation by transcription factors and microRNAs. Science 319:1785–1786
Xia H, Mao Q, Paulson HL et al (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006–1010
Morris KV, Chan SW-L, Jacobsen SE et al (2004) Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305:1289–1292
Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343–349
Chendrimada TP, Gregory RI, Kumaraswamy E et al (2005) TRBP recruits the dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436:740–744
McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3:737–747
Liang X-H, Sun H, Nichols JG et al (2017) RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther 25:2075–2092
Nowotny M, Gaidamakov SA, Crouch RJ et al (2005) Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121:1005–1016
Inoue H, Hayase Y, Iwai S et al (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett 215:327–330
Walder RY, Walder JA (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 85:5011–5015
Vickers TA, Koo S, Bennett CF et al (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 278:7108–7118
Bonham MA, Brown S, Boyd AL et al (1995) An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res 23:1197–1203
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140
Morcos PA (2007) Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. Biochem Biophys Res Commun 358:521–527
Woolf TM (1995) To Cleave or Not To Cleave: Ribozymes and Antisense. Antisense Res Dev 5:227–232
Dias N, Dheur S, Nielsen PE et al (1999) Antisense PNA tridecamers targeted to the coding region of ha-ras mRNA arrest polypeptide chain elongation1. J Mol Biol 294:403–416
Lennox KA, Behlke MA (2016) Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res 44:863–877
Lee JT (2012) Epigenetic regulation by long noncoding RNAs. Science 338:1435–1439
Mercer TR, Mattick JS (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20:300–307
Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21:1253–1261
Kher G, Trehan S, Misra A (2011) 7- Antisense Oligonucleotides and RNA Interference. In: Misra A (ed) Challenges in delivery of therapeutic genomics and proteomics. Elsevier, London, pp 325–386
Karikó K, Bhuyan P, Capodici J et al (2004) Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs 177:132–138
Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335–376
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384
Nair JK, Attarwala H, Sehgal A et al (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res 45:10969–10977
Sashital DG, Doudna JA (2010) Structural insights into RNA interference. Curr Opin Struct Biol 20:90–97
Murante RS, Henricksen LA, Bambara RA (1998) Junction ribonuclease: an activity in Okazaki fragment processing. Proc Natl Acad Sci U S A 95:2244–2249
Liu B, Hu J, Wang J et al (2017) Direct visualization of RNA-DNA primer removal from Okazaki fragments provides support for flap cleavage and exonucleolytic pathways in eukaryotic cells. J Biol Chem 292(12):4777–4788
Qiu J, Qian Y, Frank P et al (1999) Saccharomyces cerevisiae RNase H(35) functions in RNA primer removal during lagging-strand DNA synthesis, most efficiently in cooperation with Rad27 nuclease. Mol Cell Biol 19:8361–8371
Cerritelli SM, Crouch RJ (2009) Ribonuclease H: the enzymes in eukaryotes. FEBS J 276:1494–1505
Kielpinski LJ, Hagedorn PH, Lindow M et al (2017) RNase H sequence preferences influence antisense oligonucleotide efficiency. Nucleic Acids Res 45:12932–12944
Resina S, Kole R, Travo A et al (2007) Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides. J Gene Med 9:498–510
Owens DE 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102
Liu Y, Li J, Shao K et al (2010) A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31:5246–5257
Rosales C, Uribe-Querol E (2017) Phagocytosis: a fundamental process in immunity. Biomed Res Int 2017:9042851
Sansonetti PJ (2000) Phagocytosis, a cell biology view. J Cell Sci 113:3355–3356
Aderem A (2003) Phagocytosis and the Inflammatory Response. J Infect Dis 187:S340–S345
Czuprynski CJ (2016) Opsonization and Phagocytosis. In: Vohr H-W (ed) Encyclopedia of immunotoxicology. Springer, Berlin, Heidelberg, pp 674–676
Choi HS, Liu W, Misra P et al (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165–1170
Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221
Hatakeyama H, Akita H, Harashima H (2011) A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63:152–160
Mishra S, Webster P, Davis ME (2004) PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83:97–111
Suk JS, Xu Q, Kim N et al (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51
Webber MJ, Appel EA, Vinciguerra B et al (2016) Supramolecular PEGylation of biopharmaceuticals. Proc Natl Acad Sci U S A 113:14189–14194
Salvati A, Pitek AS, Monopoli MP et al (2013) Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8:137–143
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
Maeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151
Prabhakar U, Maeda H, Jain RK et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412–2417
Nakamura Y, Mochida A, Choyke PL et al (2016) Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 27:2225–2238
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989
Ferretti S, Allegrini PR, Becquet MM et al (2009) Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 11:874–881
Northey JJ, Przybyla L, Weaver VM (2017) tissue force programs cell fate and tumor aggression. Cancer Discov 7:1224–1237
Greish K (2010) Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 624:25–37
Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78:857–902
Mishra S, Heidel JD, Webster P et al (2006) Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J Control Release 116:179–191
Varkouhi AK, Scholte M, Storm G et al (2011) Endosomal escape pathways for delivery of biologicals. J Control Release 151:220–228
Stewart MP, Lorenz A, Dahlman J et al (2016) Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:465–478
Akinc A, Thomas M, Klibanov AM et al (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7:657–663
Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19:1584–1596
Pardridge WM (2007) shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 59:141–152
Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131–139
Georgieva JV, Hoekstra D, Zuhorn IS (2014) Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier. Pharmaceutics 6:557–583
Bertrand N, Wu J, Xu X et al (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25
Karimi M, Ghasemi A, Sahandi Zangabad P et al (2016) Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev 45:1457–1501
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951
Schiffelers RM, Ansari A, Xu J et al (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149
Veiman K-L, Künnapuu K, Lehto T et al (2015) PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. J Control Release 209:238–247
Kaul G, Amiji M (2005) Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 22:951–961
Hu Y, Haynes MT, Wang Y et al (2013) A Highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 7:5376–5384
Rodriguez PL, Harada T, Christian DA et al (2013) Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339:971–975
Usman WM, Pham TC, Kwok YY et al (2018) Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun 9:2359
Villa CH, Anselmo AC, Mitragotri S et al (2016) Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv Drug Deliv Rev 106:88–103
Muzykantov VR (2010) Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 7:403–427
Parodi A, Quattrocchi N, van de Ven AL et al (2013) Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 8:61–68
Hu Q, Sun W, Qian C et al (2015) Anticancer platelet-mimicking nanovehicles. Adv Mater 27:7043–7050
Anselmo AC, Modery-Pawlowski CL, Menegatti S et al (2014) Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 8:11243–11253
Kraus M, Wolf B (1996) Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. Tumour Biol 17:133–154
Estrella V, Chen T, Lloyd M et al (2013) Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 73:1524–1535
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146
Xia J, Tian H, Chen J et al (2016) pH-triggered sheddable shielding system for polycationic gene carriers. Polymers 8:141
Dimde M, Neumann F, Reisbeck F et al (2017) Defined pH-sensitive nanogels as gene delivery platform for siRNA mediated in vitro gene silencing. Biomater Sci 5:2328–2336
Sethuraman VA, Na K, Bae YH (2006) pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules 7:64–70
Li H-J, Du J-Z, Liu J et al (2016) Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano 10:6753–6761
Teotia AK, Sami H, Kumar A (2015) 1- Thermo-responsive polymers: structure and design of smart materials. In: zhang z (ed) switchable and responsive surfaces and materials for biomedical applications. Woodhead Publishing, Oxford, pp 3–43
Hoogenboom R (2014) Temperature-responsive polymers: properties, synthesis and applications. In: Aguilar MR, San Román J (eds) Smart polymers and their applications. Woodhead Publishing, Oxford, pp 15–44
Schmaljohann D (2006) Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 58:1655–1670
Twaites BR, de las HAC, Cunliffe D et al (2004) Thermo and pH responsive polymers as gene delivery vectors: effect of polymer architecture on DNA complexation in vitro. J Control Release 97:551–566
Mykhaylyk O, Zelphati O, Rosenecker J et al (2008) siRNA delivery by magnetofection. Curr Opin Mol Ther 10:493–505
Scherer F, Anton M, Schillinger U et al (2002) Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9:102–109
Bae KH, Lee K, Lee J et al (2011) Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. J Control Release 152(Suppl 1):e133–e134
Lee JH, Lee K, Moon SH et al (2009) All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 48(23):4174–4179
Medarova Z, Pham W, Farrar C et al (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13:372–377
Torchilin VP (2014) Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 13:813–827
Kelley EG, Albert JNL, Sullivan MO et al (2013) Stimuli-responsive copolymer solution and surface assemblies for biomedical applications. Chem Soc Rev 42:7057–7071
Shen Y, Fu X, Fu W et al (2015) Biodegradable stimuli-responsive polypeptide materials prepared by ring opening polymerization. Chem Soc Rev 44:612–622
Becker AL, Orlotti NI, Folini M et al (2011) Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano 5:1335–1344
Han L, Tang C, Yin C (2015) Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. Biomaterials 60:42–52
Zhuang Y, Deng H, Su Y et al (2016) Aptamer-functionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromolecules 17:2050–2062
Srinivasarao M, Low PS (2017) Ligand-targeted drug delivery. Chem Rev 117:12133–12164
Yang T, Li B, Qi S et al (2014) Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics 4:1096–1111
Yang C, Gao S, Kjems J (2014) Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. J Mater Chem B Mater Biol Med 2:8608–8615
Lee H, Lytton-Jean AKR, Chen Y et al (2012) Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 7:389–393
Venturelli L, Nappini S, Bulfoni M et al (2016) Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep 6:21629
Murata J-I, Ohya Y, Ouchi T (1997) Design of quaternary chitosan conjugate having antennary galactose residues as a gene delivery tool. Carbohydr Polym 32:105–109
Kim TH, Kim SI, Akaike T et al (2005) Synergistic effect of poly(ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes. J Control Release 105:354–366
Thapa B, Kumar P, Zeng H et al (2015) Asialoglycoprotein receptor-mediated gene delivery to hepatocytes using galactosylated polymers. Biomacromolecules 16:3008–3020
Zacco E, Hütter J, Heier JL et al (2015) Tailored presentation of carbohydrates on a coiled coil-based scaffold for asialoglycoprotein receptor targeting. ACS Chem Biol 10:2065–2072
Matsuda S, Keiser K, Nair JK et al (2015) siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol 10:1181–1187
Nair JK, Willoughby JLS, Chan A et al (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958–16961
Rajeev KG, Nair JK, Jayaraman M et al (2015) Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 16:903–908
Zhao L, Liu M, Wang J et al (2015) Chondroitin sulfate-based nanocarriers for drug/gene delivery. Carbohydr Polym 133:391–399
Xia W, Low PS (2010) Folate-targeted therapies for cancer. J Med Chem 53:6811–6824
Guo S, Huang F, Guo P (2006) Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther 13:814–820
Thomas M, Kularatne SA, Qi L et al (2009) Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann N Y Acad Sci 1175:32–39
Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo: In vivo siRNA delivery. FEBS J 277:4814–4827
York AW, Zhang Y, Holley AC et al (2009) Facile synthesis of multivalent folate-block copolymer conjugates via aqueous RAFT polymerization: targeted delivery of siRNA and subsequent gene suppression. Biomacromolecules 10:936–943
Arima H, Yoshimatsu A, Ikeda H et al (2012) Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol Pharm 9:2591–2604
Fernandes JC, Qiu X, Winnik FM et al (2012) Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomedicine 7:5833–5845
York AW, Huang F, McCormick CL (2010) Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers. Biomacromolecules 11:505–514
Roggenbuck D, Mytilinaiou MG, Lapin SV et al (2012) Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity. Auto Immun Highlights 3:119–125
Nishikawa M, Takemura S, Takakura Y et al (1998) Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J Pharmacol Exp Ther 287:408–415
Lepenies B, Lee J, Sonkaria S (2013) Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 65:1271–1281
Medina SH, Tekumalla V, Chevliakov MV et al (2011) N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 32:4118–4129
Rouet R, Thuma BA, Roy MD et al (2018) Receptor-mediated delivery of CRISPR-Cas9 endonuclease for cell-type-specific gene editing. J Am Chem Soc 140:6596–6603
Nakagawa O, Ming X, Huang L et al (2010) Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc 132:8848–8849
Tai W, Li J, Corey E et al (2018) A ribonucleoprotein octamer for targeted siRNA delivery. Nat Biomed Eng 2:326–337
Lee JB, Zhang K, Tam YYC et al (2016) A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo. Mol Ther Nucleic Acids 5:e348
Langut Y, Talhami A, Mamidi S et al (2017) PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. Proc Natl Acad Sci U S A 114:13655–13660
Li Y, Xu X-L, Zhao D et al (2015) TLR3 ligand poly IC attenuates reactive astrogliosis and improves recovery of rats after focal cerebral ischemia. CNS Neurosci Ther 21:905–913
Chen J, Gamou S, Takayanagi A et al (1994) A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett 338:167–169
Yu H, Nie Y, Dohmen C et al (2011) Epidermal growth factor–PEG functionalized PAMAM-Pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry. Biomacromolecules 12:2039–2047
Shir A, Ogris M, Wagner E et al (2006) EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 3:e6
Schaffert D, Kiss M, Rödl W et al (2011) Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res 28:731–741
Jandl JH, Inman JK, Simmons RL et al (1959) Transfer of iron from serum iron-binding protein to human reticulocytes. J Clin Invest 38:161–185
Ponka P (2004) Iron and cell proliferation: another piece of the puzzle. Blood 104:2620–2621
Le NTV, Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603:31–46
Koppu S, Oh YJ, Edrada-Ebel R et al (2010) Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release 143:215–221
Li H, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22:225–250
Pun SH, Tack F, Bellocq NC et al (2004) Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 3:641–650
Cardoso ALC, Simões S, de Almeida LP et al (2007) siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med 9:170–183
Tietze N, Pelisek J, Philipp A et al (2008) Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. Oligonucleotides 18:161–174
Yang X, Koh CG, Liu S et al (2009) Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 6:221–230
Wiley DT, Webster P, Gale A et al (2013) Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A 110:8662–8667
Huang R-Q, Qu Y-H, Ke W-L et al (2007) Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 21:1117–1125
Wei L, Guo X-Y, Yang T et al (2016) Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Int J Pharm 510:394–405
Firer MA, Gellerman G (2012) Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 5:70
Ngamcherdtrakul W, Morry J, Gu S et al (2015) Cationic polymer modified mesoporous silica nanoparticles for targeted SiRNA delivery to HER2+ breast cancer. Adv Funct Mater 25:2646–2659
Wang CY, Huang L (1987) pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci U S A 84:7851–7855
Guo J, Russell EG, Darcy R et al (2017) Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Mol Pharm 14:940–952
Lee J, Yun K-S, Choi CS et al (2012) T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem 23:1174–1180
Chen Y, Zhu X, Zhang X et al (2010) Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18:1650–1656
Bäumer S, Bäumer N, Appel N et al (2015) Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res 21:1383–1394
Di Paolo D, Brignole C, Pastorino F et al (2011) Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther 19:1131–1140
Song E, Zhu P, Lee S-K et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709–717
Sugo T, Terada M, Oikawa T et al (2016) Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release 237:1–13
Laroui H, Viennois E, Xiao B et al (2014) Fab’-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release 186:41–53
Gao J, Liu W, Xia Y et al (2011) The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32:3459–3470
Lu H, Wang D, Kazane S et al (2013) Site-specific antibody-polymer conjugates for siRNA delivery. J Am Chem Soc 135:13885–13891
Kumar P, Ban H-S, Kim S-S et al (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577–586
Derfus AM, Chen AA, Min D-H et al (2007) Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 18:1391–1396
Liu Y, Huang R, Han L et al (2009) Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30:4195–4202
Ren J, Shen S, Wang D et al (2012) The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33:3324–3333
Shao K, Huang R, Li J et al (2010) Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 147:118–126
Gao H, Zhang S, Cao S et al (2014) Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm 11:2755–2763
Huile G, Shuaiqi P, Zhi Y et al (2011) A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 32:8669–8675
Deshane J, Garner CC, Sontheimer H (2003) Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 278:4135–4144
Veiseh O, Kievit FM, Fang C et al (2010) Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 31:8032–8042
Costa PM, Cardoso AL, Mendonça LS et al (2013) Tumor-targeted Chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids 2:e100
Kievit FM, Veiseh O, Fang C et al (2010) Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 4:4587–4594
Huang R, Ke W, Han L et al (2011) Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 32:2399–2406
Wei X, Zhan C, Chen X et al (2014) Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. Mol Pharm 11:3261–3268
Wei X, Zhan C, Shen Q et al (2015) A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chem Int Ed Engl 127:3066–3070
Li Z, Zhao R, Wu X et al (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19:1978–1985
Lo A, Lin C-T, Wu H-C (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7:579–589
Kortylewski M, Swiderski P, Herrmann A et al (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925–932
Zhang Q, Hossain DMS, Nechaev S et al (2013) TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 121:1304–1315
Ni X, Castanares M, Mukherjee A et al (2011) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206–4214
Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9:537–550
Röthlisberger P, Hollenstein M (2018) Aptamer chemistry. Adv Drug Deliv Rev 134:3–21
Liao J, Liu B, Liu J et al (2015) Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery. Expert Opin Drug Deliv 12:493–506
Zhu G, Niu G, Chen X (2015) Aptamer-drug conjugates. Bioconjug Chem 26:2186–2197
Blind M, Blank M (2015) Aptamer selection technology and recent advances. Mol Ther Nucleic Acids 4:e223
Velez TE, Singh J, Xiao Y et al (2012) Systematic evaluation of the dependence of deoxyribozyme catalysis on random region length. ACS Comb Sci 14:680–687
Kwon YS, Ahmad Raston NH, Gu MB (2014) An ultra-sensitive colorimetric detection of tetracyclines using the shortest aptamer with highly enhanced affinity. Chem Commun 50:40–42
Li Y, Geyer CR, Sen D (1996) Recognition of anionic porphyrins by DNA aptamers. Biochemistry 35:6911–6922
Jiang F, Liu B, Lu J et al (2015) Progress and challenges in developing aptamer-functionalized targeted drug delivery systems. Int J Mol Sci 16:23784–23822
Hirao I, Kimoto M, Lee KH (2018) DNA aptamer generation by ExSELEX using genetic alphabet expansion with a mini-hairpin DNA stabilization method. Biochimie 145:15–21
Esposito CL, Cerchia L, Catuogno S et al (2014) Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22:1151–1163
Kim JK, Choi K-J, Lee M et al (2012) Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33:207–217
Zhou J, Li H, Li S et al (2008) Novel dual inhibitory function aptamer–siRNA delivery system for HIV-1 therapy. Mol Ther 16:1481–1489
Chu TC, Twu KY, Ellington AD et al (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res 34:e73
Yoon S, Huang K-W, Reebye V et al (2016) Targeted delivery of C/EBPα -saRNA by pancreatic ductal adenocarcinoma (PDAC)-specific RNA aptamers Inhibits tumor growth in vivo. Mol Ther 24(6):1106–1116
Yoon S, Huang K-W, Reebye V et al (2017) Aptamer-drug conjugates of active metabolites of nucleoside analogs and cytotoxic agents inhibit pancreatic tumor cell growth. Mol Ther Nucleic Acids 6:80–88
Zhou J, Preston Neff C, Swiderski P et al (2013) Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21:192–200
Zhou J, Li H, Zhang J et al (2011) Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. In: J Vis Exp
Zhou J, Lazar D, Li H et al (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575–1590
Shangguan D, Li Y, Tang Z et al (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 103:11838–11843
Wu Y, Zhang L, Cui C et al (2018) Enhanced targeted gene transduction: AAV2 vectors conjugated to multiple aptamers via reducible disulfide linkages. J Am Chem Soc 140:2–5
Lakhin AV, Kazakov AA, Makarova AV et al (2012) Isolation and characterization of high affinity aptamers against DNA polymerase iota. Nucleic Acid Ther 22:49–57
Lakhin AV, Tarantul VZ, Gening LV (2013) Aptamers: problems, solutions and prospects. Acta Naturae 5:34–43
Catuogno S, Esposito CL (2017) Aptamer cell-based selection: overview and advances. Biomedicines 5(3). pii: E49
Pranatharthiharan S, Patel MD, Malshe VC et al (2017) Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Deliv 24:20–29
Van Der Heijden JW, Oerlemans R, Dijkmans BAC et al (2009) Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 60:12–21
Tsuneyoshi Y, Tanaka M, Nagai T et al (2012) Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand J Rheumatol 41:132–140
Nakashima-Matsushita N, Homma T, Yu S et al (1999) Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42:1609–1616
Parker N, Turk MJ, Westrick E et al (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284–293
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983
Srinivasarao M, Galliford CV, Low PS (2015) Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14:203–219
Maxfield FR, McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5:121–132
Bareford LM, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59:748–758
Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30–33
Alam MR, Ming X, Fisher M et al (2011) Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem 22:1673–1681
Kong L, Alves CS, Hou W et al (2015) RGD peptide-modified dendrimer-entrapped gold nanoparticles enable highly efficient and specific gene delivery to stem cells. ACS Appl Mater Interfaces 7:4833–4843
Pritchard LK, Spencer DIR, Royle L et al (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6:7479
Sanders RW, Venturi M, Schiffner L et al (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293–7305
Raska M, Takahashi K, Czernekova L et al (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285:20860–20869
Donkor DA, Bhakta V, Eltringham-Smith LJ et al (2017) Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep 7:2102
Seiwert SD, Stines Nahreini T, Aigner S et al (2000) RNA aptamers as pathway-specific MAP kinase inhibitors. Chem Biol 7:833–843
Zhou J, Rossi JJ, Shum KT (2015) Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge. Methods Mol Biol 1297:169–185
Chan DPY, Deleavey GF, Owen SC et al (2013) Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. Biomaterials 34:8408–8415
Taratula O, Garbuzenko OB, Kirkpatrick P et al (2009) Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 140:284–293
Kim E, Jung Y, Choi H et al (2010) Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31:4592–4599
Kim HA, Nam K, Kim SW (2014) Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 35:7543–7552
Wu X, Ding B, Gao J et al (2011) Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 6:1747–1756
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Xia, X., Pollock, N., Zhou, J., Rossi, J. (2019). Tissue-Specific Delivery of Oligonucleotides. In: Gissberg, O., Zain, R., Lundin, K. (eds) Oligonucleotide-Based Therapies. Methods in Molecular Biology, vol 2036. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9670-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9670-4_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9669-8
Online ISBN: 978-1-4939-9670-4
eBook Packages: Springer Protocols